The Division of Nuclear Medicine is devoted to the early localisation and treatment of tumours, by means of functional imaging and targeted radionuclide therapy.

The Division offers traditional nuclear medicine techniques as well as new diagnostic exams, such as sentinel node lymphoscintigraphy, radioguided occult lesion localisation (ROLL) and peptide-guided whole body scans. Recently, a positron emission tomograph was installed and 18FDG-PET scans are routinely performed in the diagnosis, staging and follow up of various types of cancer. The Division is one of the few in Europe having protocols of radionuclide therapy of solid tumours with new radiolabelled molecules that show high affinity for tumour cells, namely monoclonal antibodies, avidin-biotin and radiolabelled peptides. The Nuclear Medicine Division has a special hospitalisation section with 8 beds in rooms set aside for radionuclide therapy.

The Division possesses one PET/CT scanner, two double-head gamma-cameras, one of which is equipped with a coincidence system, and one single head gamma-camera. Moreover, the Division is fully equipped for the synthesis of 18FDG and its quality control and possesses three hot labs for the preparation of radiopharmaceuticals with different types of emission (gamma, beta+ and beta-), both for diagnosis and therapy.

The Division has an agreement with various Universities in Italy, for the educational activity in the School of Specialisation in Nuclear Medicine, to spread new therapeutic modalities in the field of Radiometabolic Therapy. The Nuclear Medicine Division is hosting many young fellows from different countries, for pre-clinical and clinical research activities, to foster future collaborations.